Research.Patient.info
Hereditary Spastic Paraplegia Type 50 (SPG50) research hub
2 indexed studies · 0 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)
This phase 3 trial looks at a new gene therapy called Melpida for people with spastic paraplegia type 50 (SPG50). SPG50 is a rare genetic condition causing muscle stiffness and developmental delays. Researchers want to see if a single dose into the spinal fluid helps improve movement and learning over three years.
Spain - authorisedTherapeutic exploratory (Phase II)
A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)
This study is looking into a new treatment called Melpida for a rare genetic condition called SPG50, which affects movement. It aims to see if Melpida can help improve how people with SPG50 move by tracking their walking and other physical abilities over time.
Italy